As I see it

Share this article:
In January, FDA announced the launch of a new “FDA Basics for Industry,” the most promising of its faltering transparency steps to date.
The announcement and the site itself showed a determination to accommodate the concerns of product sponsors who pay so much to FDA in user fees— unlike the agency's responses to those who don't.
They continue to battle FDA's growing penchant for secrecy. Recently, I peppered the agency's press office with questions about how many members of the public had asked to speak at a public advisory panel hearing and got only evasions.
I fault the initiative's design. Instead of assigning it to unconflicted outsiders to manage, this initiative was run by insiders.
Here's my proposal to correct this:
1. Under presidential directive, accept the premise that everything FDA does is to benefit the public, and that the public at large is to define the meaning of its “benefit” in this context.
2. Using an external federal scientific agency organizationally unrelated to FDA and a jury of 12 public volunteers who demonstrate no conflicts of interest, reach out to learn their expectations of FDA.
3. Create an open public process to examine and adopt inputs received from the public as to their expectations.
4. Open all FDA processes and records to lawful public access as required by the results of (3) above.
5. Where laws impede public access, submit all these to a public review process and submit the findings to “town hall” meetings around the country.
6.  Submit resulting recommendations to the country and to Congress.
James G. Dickinson is editor of Dickinson's FDA Webview (
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in As I See It

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in As I See It

As I See It: Patient Centricity

As I See It: Patient Centricity

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

As I See It: FDA's social-media moves

As I See It: FDA's social-media moves

FDA has insisted that its antique regulations can address every new promotional challenge

As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications